article thumbnail

STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show

STAT

In study documents, Mount Sinai doctors said the biopsies result in “the same amount of tissue loss” and “in effect, the same level of risk” for patients as standard DBS, because they are removing tissue that would otherwise be cauterized.

article thumbnail

PDA revises report on glass container manufacturing

European Pharmaceutical Review

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. Specifically, the document covers the development process of glass containers for pharmaceutical products, glass container sampling as well as definition of lots.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Heart Failure Guideline Updates in 2021

Med Ed 101

There are a few important heart failure guideline updates in the works to the American College of Cardiology’s Heart Failure Guidelines, last published in 2013. This document […]. The post Heart Failure Guideline Updates in 2021 appeared first on Med Ed 101.

article thumbnail

Federal Court updates guidance on COVID-19

Pharma in Brief

Also on January 18, 2021, the FC issued a new Practice Direction outlining its Document Retention Schedule, including new plans for the destruction of certain archived documents. Service of Documents. Parties may serve their documents electronically pursuant to the Federal Courts Rules. Document Retention Schedule.

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

The FDA granted full approval to Par’s generic on 28 March, 2013. According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before generic versions reached the market.

article thumbnail

Federal Court of Appeal provides guidance on disclosure exemptions in ATI requests

Pharma in Brief

As we previously reported , the ATI Request concerned Health Canada submission documents for Fortekor, an Elanco Canada Limited ( Elanco ) veterinary drug product. In the judgment, “Records” had been defined to mean the entire third-party request, which included documents that Elanco conceded were not confidential and could be disclosed.

article thumbnail

Building a better future for people with rare diseases in all four UK nations

pharmaphorum

Published in January, the document replaces 2013’s UK Strategy for Rare Diseases and sets out four priorities for the next five years: faster diagnosis, increasing awareness among healthcare professionals, the better coordination of care, and improving access to specialist care, treatments, and drugs.